California Securities Fraud Attorney Call Today 800-699-1881
California Securities Fraud Lawyer Firm Overview Attorney Profiles Recoveries Obtained Frequently Asked Questions Testimonials Contact Us
information center
Attorney Advertising Disclaimer
Securities
Broker Misrepresentation
Brokerage Firms Sued
FINRA
Structured Products
Hedge Fund Losses
Recognizing Investment Losses
Recovery of Investment Loss
Securities Arbitration
Reverse Convertible
Misconduct
Securities Fraud
Securities Mediation
Securities Litigation
Stock/ Investment Losses
Suitability/ Unsuitability
Unauthorized Trading
Common Claims
Products
Frequently Asked Questions
Attorney Referrals
Video Center
securities fraud blog
legal blog Click here for a free case evaluation. Read our Articles on Securities Related Issues here. have a question resources
contact us
Name:
Email:
Phone:
Are you a new client?
Message:
10 Avvo avvo badge
If you need help recovering your losses contact us today. View our complete list of brokerage firms and banks we've sued.

SEC Charges Barred First Allied Broker Paul Rampoldi, Convicted of Fraud in Ardea Scheme

The Securities and Exchange Commissioner barred San Diego's Paul Thomas Rampoldi from acting as a broker, several months after Rampoldi's conviction in US District Court for the Southern District of California of conspiracy to commit securities fraud, wire fraud, and money laundering.

The Rampoldi conviction and bar relates to SEC's 2015 bar of Southern California brokers Chad Edward Wiegand and Akis Costas Eracleous, formerly of National Planning Corp. Wiegand and Eracleous were similarly accused of insider trading, earning $530,000 in illegal trading profits, which includes ill-gotten commissions.

Though Rampoldi's was most recently registered via FINRA with First Allied Securities of San Diego, the SEC order pertains to alleged insider trading involving Ardea Biosciences, Inc. securities while Rampoldi was associated with National Planning Corp, also of San Diego, similar to the Wiegand and Eracleous charges.

SEC Order #3-18862

According to the findings, Rampoldi (CRD #2183491) participated in the insider trading scheme to profit in advance of two major announcements from the California-based company Ardea Biosciences, which had been acquired by pharmaceutical firm AstraZeneca. A report on Rampoldi's conviction indicates that the insider information allegedly was leaked from Ardea by IT director Michael Fefferman to Wiegand, who shared the nonpublic intel with Eracleous, who in turn passed it on to Rampoldi and another person charged in the scheme, William Scott Blythe.

The SEC said that Rampoldi made approximately $90,000 in illicit profits by trading ahead of the announcements using nonpublic information. The order additionally bars Rampoldi from participating in any offering of a penny stock.

In 2000, Rampoldi settled with a customer who alleged that he misrepresented mutual funds; the SEC bar is Rampoldi's sixth disclosure.

If you have invested with Paul Thomas Rampoldi in Ardea Biosciences/AstraZeneca or with any other broker or financial adviser whose use of nonpublic and confidential information and associated illicit insider trading or other illegal activity has proven harmful to your investments or interests, please call The Law Offices of Jonathan W. Evans & Associates at (800) 699-1881 for investigation and consultation.

accolades
The Law Offices of Jonathan W. Evans & Associates - California Securities Fraud Attorney
Located at 12711 Ventura Boulevard, Suite #440 Studio City, CA 91604. View Map
Phone: (800) 699-1881 | Local Phone: (818) 760-9880.
Website: